The recent formation of an index focused on health product innovators illustrates both the upside and the stability of the medtech arena.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which [...]
In a prior post, I sought to explore the shifting nature of the medical industry, from clearly defined categories of devices, drugs and diagnostics to a spectrum of products that defy categorization into any one category and instead frequently qualify as multiple.
…Competition in the medical product industry has long since changed from being defined as [...]
(Continued from here)
The dynamics behind these products’ success:
Significant cost-effectiveness arguments can be made for products that avoid blood transfusions or reduce the quantities of blood transfusion products required. Approximately 8 million patients worldwide would benefit directly from increased usage of hemostats, sealants and glue products to reduce bleeding during cardiovascular, orthopaedic, urologic, and other general surgical [...]
(Continued from here)
The dynamics behind these products’ success includes the pragmatic benefits that ensure their ready adoption in the clinical setting:
Use of cyanoacrylate glues for closure has established a considerable following in all regions of the world. Conservative accident and emergency costs for closure of a small bleeding trauma laceration with sutures, local anaesthetic, antibiotic [...]
There are many reasons underlying the explosive growth of the worldwide markets for surgical sealants, hemostasis, wound closure and anti-adhesion.
The market potential for products in the surgical securement field is driven by a combination of new technologies coming to market and expanding caseload for which these technologies are applicable. The potential for these products continues [...]
The medtech sector remains as compelling a safe haven as any other for investment. Nonetheless, the depth of the recession and the reach of its negative impact (real or perceived) are enough that medtech is not immune to recessions worries. Of course, this is obvious enough to anyne close to the subject. But so what?
How [...]
If one is in the position of needing to look to the future of medical technology (and who in this industry is not?)—to identify opportunities or predict challenges in the market—then it is hard to not factor into it two very different current trends and play them out toward the resulting future market impact. One [...]
Medtronic is the predominant player in the energy-based therapies market. With global sales of nearly $4.9 billion attributable to energy-based products, it controls over half of the cardiac rhythm market and almost a quarter of all energy-based product sales. Boston Scientific, also focusing on cardiac arrhythmias, comes next in the revenues table with a [...]
I offer a set of perspectives from ITECS Insider on the most significant headlines in the medical device industry in 2008 with potential impact in 2009. I recommend you read them in full, but here are the highlights of opinion:
"Nothing will impact the medical device manufacturing industry in 2009 more than the subprime mortgage meltdown and [...]